VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 40 filers reported holding VERONA PHARMA PLC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $976,484 | -63.9% | 59,907 | -53.2% | 0.00% | – |
| Q2 2023 | $2,706,914 | +53.7% | 128,047 | +46.0% | 0.00% | – |
| Q1 2023 | $1,761,016 | -77.1% | 87,700 | -70.1% | 0.00% | -100.0% |
| Q4 2022 | $7,676,550 | +136.2% | 293,783 | -7.6% | 0.00% | 0.0% |
| Q3 2022 | $3,250,000 | +1575.3% | 318,000 | +586.8% | 0.00% | – |
| Q2 2022 | $194,000 | +113.2% | 46,300 | +152.6% | 0.00% | – |
| Q1 2022 | $91,000 | -88.2% | 18,333 | -84.1% | 0.00% | – |
| Q4 2021 | $772,000 | +819.0% | 114,960 | +648.2% | 0.00% | – |
| Q3 2021 | $84,000 | -33.3% | 15,364 | +2.2% | 0.00% | – |
| Q1 2021 | $126,000 | -25.0% | 15,035 | -37.5% | 0.00% | – |
| Q4 2020 | $168,000 | +90.9% | 24,074 | +56.6% | 0.00% | – |
| Q4 2019 | $88,000 | – | 15,375 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
| Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
| Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
| Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
| NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
| Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
| Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
| Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
| Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
| Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |